Loomis, Sayles & Company
NKTR icon

Loomis, Sayles & Company’s Nektar Therapeutics NKTR Stock Holding History

Loomis, Sayles & Company’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2
Closed -$3K – 916
2018
Q1 		$3K Buy
+2
New +$2.58K ﹤0.01% 861
2016
Q4 		– Sell
-65,235
Closed -$16.8M – 1079
2016
Q3 		$16.8M Buy
65,235
+65,207
+232,882% +$16.8M 0.04% 312
2016
Q2 		$6K Sell
28
-28
-50% -$6.26K ﹤0.01% 827
2016
Q1 		$12K Buy
+56
New +$10.8K ﹤0.01% 792

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Loomis, Sayles & Company's NKTR Position: Q2 2018 in Review

Loomis, Sayles & Company sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 2 shares — an estimated $3K sold.

Loomis, Sayles & Company first reported a position in NKTR in Q1 2016 and held it in 4 quarters. The position peaked at $16.8M in Q3 2016. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Loomis, Sayles & Company reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 2 Nektar Therapeutics shares in Q2 2018, an estimated $3K.
  • Loomis, Sayles & Company first reported a position in Nektar Therapeutics in Q1 2016 and held it in 4 quarters.
  • Loomis, Sayles & Company's Nektar Therapeutics position peaked at $16.8M in Q3 2016.
  • 379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Loomis, Sayles & Company's 13F filing for Q2 2018, filed 14 Aug 2018.